Results 41 to 50 of about 7,117 (221)

Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation [PDF]

, 2019
Background Accurate protein quantification is a vital prerequisite for generating meaningful predictions when using systems biology approaches, a method that is increasingly being used to unravel the complexities of sub cellular interactions and as part
Bye, Alexander P., Di, Ying, Dunster, Joanne L., García, Ángel, Gibbins, Jonathan M., Haining, Elizabeth J,, Hardy, Alexander T., Nieswandt, Bernhard, Pallini, Chiara, Pike, Jeremy A., Pollitt, Alice Y., Poulter, Natalie S., Sage, Tanya, Sowa, Marcin A., Unsworth, Amanda J., Watson, Steve P.   +15 more
core   +4 more sources

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Journal of Hematology & Oncology, 2022
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension.
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison   +17 more
doaj   +1 more source

Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia [PDF]

, 2016
MicroRNAs (miRNAs) are small regulatory molecules that negatively regulate gene expression by base-pairing with their target mRNAs. miRNAs have contribute significantly to cancer biology and recent studies have demonstrated the oncogenic or tumor ...
Ashrafi Dehkordi, Korosh., Fathi, Fardin, Ganji-Arjenaki, Mahboube, Hakhamaneshi, Mohammad Saeed., Hashemzadeh-Chaleshtori, Morteza., Jalili, Ali., Mahmoodian Sani, Mohammad Reza., Nikkhoo, Bahram., Roshani, Daem., Sharifi, Mohamadreza.   +9 more
core   +1 more source

Mechanisms of tumor cell resistance to the current targeted-therapy agents [PDF]

, 2016
Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that
Hojjat Farsangi, Mohammad, Jadidi Niaragh, Farhad, Khamisipour, Gholamreza, Sotoodeh Jahromi, Abdolreza, zandi, Keivan   +4 more
core   +2 more sources

New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease [PDF]

, 2019
open21siopenAresu, Luca; Ferraresso, Serena; Marconato, Laura; Cascione, Luciano; Napoli, Sara; Gaudio, Eugenio; Kwee, Ivo; Tarantelli, Chiara; Testa, Andrea; Maniaci, Chiara; Ciulli, Alessio; Hillmann, Petra; Bohnacker, Thomas; Wymann, Matthias P ...
Aresu, Luca, Bertoni, Francesco, Bohnacker, Thomas, Cascione, Luciano, Ciulli, Alessio, Comazzi, Stefano, Dalla Rovere, Giulia, Ferraresso, Serena, Gaudio, Eugenio, Giannuzzi, Diana, Giantin, Mery, Hillmann, Petra, Kwee, Ivo, Maniaci, Chiara, Marconato, Laura, Milan, Massimo, Napoli, Sara, Riondato, Fulvio, Tarantelli, Chiara, Testa, Andrea, Wymann, Matthias P.   +20 more
core   +6 more sources

The role of acalabrutinib in adults with chronic lymphocytic leukemia

Therapeutic Advances in Hematology, 2021
The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic
Bita Fakhri, Charalambos Andreadis
doaj   +1 more source

Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling

Pharmaceuticals, 2021
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem.
Yu-Kai Su, Oluwaseun Adebayo Bamodu, I-Chang Su, Narpati Wesa Pikatan, Iat-Hang Fong, Wei-Hwa Lee, Chi-Tai Yeh, Hsiao-Yean Chiu, Chien-Min Lin   +8 more
doaj   +1 more source

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

Cancer Management and Research, 2020
Krista Isaac,1 Anthony R Mato2 1Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence: Krista ...
Isaac K, Mato AR
doaj  

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies

Frontiers in Oncology, 2021
The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chronic lymphocytic
Sining Zhu, Sining Zhu, Jaeyong Jung, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale, Samantha Gokhale, Ping Xie, Ping Xie   +9 more
doaj   +1 more source

Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS). [PDF]

Ann Hematol
Acalabrutinib is a second-generation BTK inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) after demonstrating efficacy and safety in clinical trials.
Quinquenel A, Leprêtre S, Dilhuydy MS, Bussot L, Marjanovic Z, Benbrahim O, Guièze R, Santagostino A, Dartigeas C, Feugier P, Roos-Weil D, Damaj G, Laribi K, Ysebaert L, Levy V.   +14 more
europepmc   +2 more sources